Literature DB >> 19609331

[Helicobacter pylori 25 years after (1983 -2008): epidemiology, microbiology, pathogenics, diagnostics and treatment].

Alberto Ramírez Ramos1, Rolando Sánchez Sánchez.   

Abstract

EPIDEMIOLOGY: People have been infected by this bacteria 58,000 years ago. Prevalence of infection varies in different nation. In developing countries infection is acquired in early childhood. The forms of infection are/fecal-oral, oral-oral an gastro oral. In Perú we found same prevalence in the coast, jungle and sierra and described that water is one of the ways of infection.MICROBIOLOGY: Three strains predominant in Spanish, Asiatic and people from India have been identified. DNA has 1.65 million bases. Different factors of virulence, enzymes and toxins have also been described. PATHOGENESIS: Inflamatory response; neutrophiles, lymphocytes T and B, plasma cells, macrophages.METHODS OF DIAGNOSIS: Invasive and non invasive procedures. THERAPY: Different treatment schemes are described: 1st, 2nd, 3rd lines, rescue therapies. Secondary reactions, alternative schemes, recurrence, reinfection and experience in Perú are also described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609331

Source DB:  PubMed          Journal:  Rev Gastroenterol Peru        ISSN: 1022-5129


  5 in total

1.  Association of Progranulin Gene Expression from Dyspeptic Patients with Virulent Helicobacter pylori Strains; In Vivo Model.

Authors:  Claudia Troncoso; Mónica Pavez; Álvaro Cerda; Victor Manríquez; Aurora Prado; Edmundo Hofmann; Eddy Ríos; Armando Sierralta; Luis Copelli; Leticia Barrientos
Journal:  Microorganisms       Date:  2022-05-10

2.  In silico experiment with an-antigen-toll like receptor-5 agonist fusion construct for immunogenic application to Helicobacter pylori.

Authors:  Mohamad Ali Haghighi; Ashraf Mohabati Mobarez; Ali Hatef Salmanian; Mohamad Moazeni; Mohamad Reza Zali; Mehdi Sadeghi; Jafar Amani
Journal:  Indian J Hum Genet       Date:  2013-01

3.  Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.

Authors:  Jia-Li Hu; Jun Yang; Yin-Bin Zhou; Ping Li; Ran Han; Dian-Chun Fang
Journal:  Saudi J Gastroenterol       Date:  2017 Sep-Oct       Impact factor: 2.485

4.  Anti-Helicobacter pylori Properties of the Ant-Venom Peptide Bicarinalin.

Authors:  Jesus Guzman; Nathan Téné; Axel Touchard; Denis Castillo; Haouaria Belkhelfa; Laila Haddioui-Hbabi; Michel Treilhou; Michel Sauvain
Journal:  Toxins (Basel)       Date:  2017-12-29       Impact factor: 4.546

5.  Local Immune Response in Helicobacter pylori Infection.

Authors:  Derya Kivrak Salim; Mehmet Sahin; Sadi Köksoy; Haydar Adanir; Inci Süleymanlar
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.